Abstract
Get full access to this article
View all access options for this article.
References
1.
Gaston
RS
Deierhoi
MH
Patterson
T
OKT3 first-dose reaction: Association with T cell subsets and cytokine release . Kidney Int
1991 ; 39 : 141 –8 .
2.
Tood
PA
Brogden
RN
. Muromonab CD3: A review of its pharmacology and therapeutic potential . Drugs
1989 ; 37 : 871 –99 .
3.
Hooks
MA
Wade
CS
Millikan
J
. Muromonab CD-3: A review of its pharmacology, pharmacokinetics, and clinical use in transplantation . Pharmacotherapy
1991 ; 11 : 26 –37 .
4.
Emmons
C
Smith
J
Flanigan
M
. Cerebrospinal fluid inflammation during OKT3 therapy . Lancet
1986 ; 2 : 510 –1 .
5.
Martin
MA
Massanari
RM
Nghiem
DD
. Nosocomial aseptic meningitis associated with administration of OKT-3 . JAMA
1988 ; 259 : 2002 –5 .
6.
Roden
J
Lintmalm
GBG
Husberg
BS
. Cerebrospinal fluid inflammation during OKT-3 therapy (letter) . Lancet
1987 ; 2 : 272 .
7.
Thistlethwaite
JR
Gaber
AO
Haag
BW
OKT-3 treatment of steroid-resistant renal allograft rejection . Transplantation
1987 ; 43 : 176 –84 .
8.
Miller
RA
Maloney
DG
McKillop
J
In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia . Blood
1981 ; 58 : 78 –86 .
9.
Birnbaum
G
. Studies on brain-thymus cross-reactive antigens . Brain Res
1975 ; 84 : 11 –21 .
10.
Williams
AF
Gagnon
J
. Neuronal cell Thy-1 glycoprotein: Homology with immunoglobulin . Science
1982 ; 216 : 696 –703 .